Targeting ADRB2 enhances sensitivity of non-small cell lung cancer to VEGFR2 tyrosine kinase inhibitors

Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitors (TKIs) have achieved remarkable clinical progress in the treatment of non-small-cell lung cancer; however, resistance has limited their therapeutic efficacy. Therefore, understanding the mechanisms of VEGF-TKI and ICI...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yingzhuo, Wang, Jian, Wang, Xu, Zhou, Xiaoshu, Tang, Jing, Jie, Xiaohua, Yang, Xijie, Rao, Xinrui, Xu, Yunhong, Xing, Biyuan, Li, Zhenyu, Wu, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786837/
https://www.ncbi.nlm.nih.gov/pubmed/35075132
http://dx.doi.org/10.1038/s41420-022-00818-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786837/
https://www.ncbi.nlm.nih.gov/pubmed/35075132
http://dx.doi.org/10.1038/s41420-022-00818-8

Ejemplares similares